Gunderson Dettmer represented Amgen in connection with the launch of AmMax Bio, in partnership with LifeMax Laboratories. In the transaction, Amgen provided to AmMax an exclusive worldwide license for the right to develop, manufacture and commercialize AMG 820, a monoclonal antibody against the colony-stimulating factor 1 receptor (“CSF-1R”) that has completed Phase I/II clinical studies in solid tumors.  AmMax Bio will focus on treating orphan diseases.

The Gunderson deal team was led by partners Kirt Shuldberg and Brendan McCarthy and included Colin Chapman, Brittany Nicely and Richard Sapien.

In an announcement of the deal Larry Hsu, LifeMax and AmMax CEO said, “The licensing of AMG 820 fits very well with our focus on developing first-in-class or best-in-class therapies for orphan diseases with significant unmet needs. We look forward to bringing this much needed therapy to people with TGCT and other orphan diseases that involve CSF-1/CSF-1R biology.”